UberDoc Health Technologies Announces Leadership Transition
Boston, Massachusetts--(Newsfile Corp. - May 15, 2026) - UberDoc Health Technologies Corp. (CSE: APPT) (FSE: 4KL0), a direct-pay healthcare marketplace connecting patients with board-certified specialists at transparent, upfront prices, today announced a leadership transition. Sean Kearney is departing as Chief Executive Officer, and founder Dr. Paula Muto has been named Interim Chief Executive Officer, as of Friday, May 15.
2026-05-15 8:00 PM EDT | Apptly Health Technologies Corp.
Promino Announces Closing of Second Tranche of Private Placement
Burlington, Ontario--(Newsfile Corp. - May 15, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company"), a performance nutrition company focused on clinically validated amino acid formulations, is pleased to announce that, further to its press releases dated March 13, April 22 and May 5, 2026, the Company has closed a second tranche (the "Second Tranche") of its private placement, issuing an aggregate of 13,437,000 unit
Aliments / boissons, Sports, Santé
2026-05-15 6:29 PM EDT | Promino Nutritional Sciences, Inc.
Restart Life Sciences Advances New Product Relaunch Utilizing Acquired Intellectual Property Portfolio
Vancouver, British Columbia--(Newsfile Corp. - May 15, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an operational update regarding the strategic trademark licensing agreement previously announced on March 14, 2025. Over the past year, management has been actively working toward product launches leveraging the intellectual property (IP) and valuable business insights acquired under the agreement. Th
Technologies, Biotechnologies, Santé
2026-05-15 4:00 PM EDT | Restart Life Sciences Corp.
ADIA Nutrition, Inc. Reports Strong Revenue Growth and Operational Momentum for First Quarter 2026
Winter Park, Florida--(Newsfile Corp. - May 15, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced nutrition and regenerative health solutions, today announced its 3rd party reviewed financial results for the first quarter ended March 31, 2026, highlighting significant year-over-year revenue growth and continued expansion of its biologics and medical procedures segments.
Soins de santé et hôpitaux, Santé
2026-05-15 7:59 AM EDT | Adia Med Inc.
AllStar Global Brands Announces Strategic Partnership with Riccione Femminile Calcio
Ontario and Riccione, Italy--(Newsfile Corp. - May 14, 2026) - AllStar Global Brands (OTCID: ALST) ("ASGB") is pleased to announce that an agreement has been reached to acquire a 60% ownership stake in Riccione Femminile Calcio for €50,000, marking the beginning of a long-term strategic partnership focused on developing women's football and international player pathways. As part of the agreement, ASGB will provide financial assistance, operational support, and access to d
Soins de santé et hôpitaux, Commerce de détail, Santé
2026-05-14 10:37 AM EDT | AllStar Health Brands, Inc.
Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration(TM)
Reno, Nevada--(Newsfile Corp. - May 14, 2026) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a medical device company advancing regenerative medicine through its patented bioregenerative extracellular matrix platform, today unveiled a new defining identity: Architecting Bioregeneration™.
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-14 8:30 AM EDT | Conexeu Sciences Inc.
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Research
Toronto, Ontario--(Newsfile Corp. - May 14, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-05-14 8:30 AM EDT | Rhelion Life Sciences Corp.
Custom Health Announces Appointment of Chief Financial Officer and Board of Directors and Shareholder Approval for Proposed Public Listing
Jason Nalewany has been appointed as Chief Financial Officer of Custom Health and, following the completion of the Arrangement, the Resulting Issuer. Jason will support both companies by providing public company compliance, financial reporting, capital allocation and long-term growth strategy. The Resulting Issuer and the operations of Custom Health will be supported by an experienced Board of Directors that bring deep expertise across healthcare, technology, capital markets and
Technologies, Pharmaceutique, Santé
2026-05-14 7:00 AM EDT | Custom Health Holdings Inc.
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of April Two-lens
Biotechnologies, Pharmaceutique, Santé
2026-05-14 7:00 AM EDT | BioHarvest Sciences Inc.
TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product
Highlights Granted Patent covers the design of VIVI Cap Smart™ across major international, growing market Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic discussions with appliance manufacturers Design term extends through May 16, 2039 Company enters into f
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-05-14 3:00 AM EDT | TempraMed Technologies Ltd.
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 25,347,133 common shares, representing 69.754% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in th
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-13 8:41 PM EDT | Profound Medical Corp.
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceu
Biotechnologies, Pharmaceutique, Santé
2026-05-13 5:32 PM EDT | BioHarvest Sciences Inc.
Mobile-health Network Solutions Enters into Non-Binding Strategic Memorandum to Facilitate Up to US$100 Million in Private Equity Funding for AI-Powered Healthcare Expansion
Singapore, Singapore--(Newsfile Corp. - May 13, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI-powered digital health platform, today announced that it has entered into a Letter of Memorandum with White Group Pte. Ltd. (Singapore) ("White Group") outlining a strategic collaboration to facilitate private equity funding of up to US$100 million to support MNDR's AI-powered healthcare expansion and digital health infrastr
2026-05-13 9:17 AM EDT | Mobile-health Network Solutions
Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders overwhelmingly approved the Company's proposed corporate name change at the Company's annual general and special meeting of shareholders ("Shareholders") held on Monday, May 11, 2026 at the Company's office in Toronto (the "Meeting"). The special resolution approving t
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-05-13 9:12 AM EDT | Rhelion Life Sciences Corp.
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director. At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Pha
2026-05-13 8:00 AM EDT | BetterLife Pharma Inc.
RETRANSMISSION: DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid, eye-based diagnostic technologies, is pleased to announce that on May 12, 2026, it has entered into a definitive exclusive global license agreement for the commercialization of the CLARIFY eye imaging platform, A breakthrough technology enabling blood analysis through a simple eye scan, eliminating the need for ne
2026-05-13 8:00 AM EDT | DiagnosTear Technologies Inc.
BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals - In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Colum
Biotechnologies, Pharmaceutique, Santé
2026-05-13 8:00 AM EDT | BioHarvest Sciences Inc.
Charlotte's Web First Quarter 2026 Financial Results
Louisville, Colorado--(Newsfile Corp. - May 13, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) ("Charlotte's Web" or the "Company"), a botanical wellness innovation company and the market leader in cannabidiol (CBD) hemp extract wellness products, today announced results for the quarter ended March 31, 2026. All amounts are expressed in U.S. dollars. TRANSACTION AND SUBSEQUENT EVENTS UPDATE Propose
2026-05-13 7:07 AM EDT | Charlotte's Web Holdings, Inc.
Restart Life Sciences Leverages Amazon Logistics for Strategic Entry of Holy Crap Foods into U.S. Market
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc., is preparing for its official entry into the United States market. This expansion marks a pivotal milestone in the Company's North American growth strategy under its new leadership team. While the brand previously maintained a broader internatio
Technologies, Biotechnologies, Santé
2026-05-13 6:00 AM EDT | Restart Life Sciences Corp.
TelyRx Announces First Quarter 2026 Financial Results
Clearwater, Florida--(Newsfile Corp. - May 12, 2026) - TelyRx Holdings Inc. (TSX: TELY) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced financial results for the first quarter ended March 31, 2026. All dollar amounts are expressed in U.S. dollars. Highlights for the First Quarter of 2026 Revenue increased to $19.4 million, compared to $14.3 million in Q
Soins de santé et hôpitaux, Santé
2026-05-12 5:57 PM EDT | TelyRx